Mirum Pharmaceuticals, Inc. Retained Earnings
Mirum Pharmaceuticals, Inc. (MIRM) had Retained Earnings of -$1.52 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-05
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$1.52B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$1.46B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$667.54M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$661.81M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$1.52B 10-Q · filed 2026-08-05 |
| 2026-03-31 | -$1.46B 10-Q · filed 2026-05-06 |
| 2025-12-31 | -$667.54M 10-Q · filed 2026-08-05 |
| 2025-09-30 | -$661.81M 10-Q · filed 2025-11-04 |
| 2025-06-30 | -$664.72M 10-Q · filed 2025-08-06 |
| 2025-03-31 | -$658.86M 10-Q · filed 2025-05-07 |
| 2024-12-31 | -$644.18M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$620.39M 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$606.16M 10-Q · filed 2024-08-07 |
| 2024-03-31 | -$581.52M 10-Q · filed 2024-05-08 |
| 2023-12-31 | -$556.24M 10-K · filed 2025-02-26 |
| 2023-09-30 | -$520.58M 10-Q · filed 2023-11-02 |
| 2023-06-30 | -$496.99M 10-Q · filed 2023-08-07 |
| 2023-03-31 | -$422.95M 10-Q · filed 2023-05-04 |
| 2022-12-31 | -$392.82M 10-K · filed 2024-03-15 |
| 2022-09-30 | -$356.39M 10-Q · filed 2022-11-09 |
| 2022-06-30 | -$320.69M 10-Q · filed 2022-08-04 |
| 2022-03-31 | -$293.76M 10-Q · filed 2022-05-05 |
| 2021-12-31 | -$257.16M 10-K · filed 2023-03-08 |
| 2021-09-30 | -$314.70M 10-Q · filed 2021-11-15 |
| 2021-06-30 | -$267.60M 10-Q · filed 2021-08-05 |
| 2021-03-31 | -$223.70M 10-Q · filed 2021-05-06 |
| 2020-12-31 | -$173.17M 10-K · filed 2022-03-09 |
| 2020-09-30 | -$135.97M 10-Q · filed 2020-11-12 |
| 2020-06-30 | -$114.46M 10-Q · filed 2020-08-06 |
| 2020-03-31 | -$91.21M 10-Q · filed 2020-05-07 |
| 2019-12-31 | -$69.90M 10-K · filed 2021-03-09 |
| 2019-09-30 | -$51.95M 10-Q · filed 2019-11-06 |
| 2019-06-30 | -$36.86M 10-Q · filed 2019-08-28 |
| 2018-12-31 | -$17.35M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |